Quanterix

124 articles with Quanterix

• Quanterix to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum

  11/13/2018

  Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity Medical Technologies & Diagnostic Forum,

• Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

  11/7/2018

  Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products

• Quanterix Expanding Transformative Biomarker Technology Portfolio Into Oncology

  11/7/2018

  Launching Test Bed for up to 10-plex assays with Simoa Sensitivity and Specificity to Advance Cancer Research

• Quanterix Corporation Releases Operating Results for Third Quarter 2018

  11/1/2018

  85% revenue growth

• Quanterix to Release Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 1, 2018

  10/25/2018

  Quanterix Corporation today announced that it will release its financial results for third quarter 2018 after the close of trading on Thursday, November 1, 2018.

• Quanterix Announces Collaboration with OncoGenesis to Develop Cervical Screening Test

  10/22/2018

  Quanterix’ technology to be used in multiplex diagnostic test for cervical disease detection

• Quanterix’ Simoa Technology Powers Record Number of Presentations and Poster Sessions at ECTRIMS 2018

  10/9/2018

  International multiple sclerosis conference features 35 new studies using Simoa technology demonstrating potential of Neurofilament light chain (NfL) as a reliable and sensitive disease biomarker

• Quanterix’ Simoa Technology Reveals Link Between Soccer Headers and Concussions for the First Time

  9/26/2018

  New research marks the latest example of neurofilament light chain (NfL) as a critical biomarker for detecting brain injuries

• Quanterix CEO Kevin Hrusovsky Leads Webinar on How Biomarkers are Empowering Drug Development

  9/11/2018

  Top researchers join precision health visionary for an in-depth discussion examining how biomarkers are innovating the drug development process and shortening approval times

• Quanterix to Speak at Wells Fargo Securities 2018 Healthcare Conference

  9/5/2018

  Company also attending Citi’s 13th Annual Biotech Conference

• Quanterix Corporation Releases Operating Results for Second Quarter 2018

  8/8/2018

  66% revenue growth

• Simoa Technology Unlocks Insights from Previously Obscure Biomarker

  8/6/2018

  Neurofilament light chain (NfL) proves to be a transformative biomarker for understanding wide range of neurological conditions and advancing clinical trials

• Quanterix to Present at the Canaccord Genuity 38th Annual Growth Conference

  7/30/2018

  Quanterix Corporation announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity 38th Annual Growth Conference, on Thursday, Aug. 9, 2018 at 10 a.m., EDT at the InterContinental Boston.

• Quanterix to Release Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018

  7/26/2018

  Quanterix Corporation announced that it will release its financial results for second quarter 2018 after the close of trading on Wednesday, August 8, 2018.

• NuProbe Forms Scientific Advisory Board and Appoints New Director

  7/24/2018

  ​NuProbe Global announced today the formation of its Scientific Advisory Board (SAB) with genomics pioneers George M. Church, Ph.D. and David R. Walt, Ph.D.

• Quanterix’ Ultra-Sensitive Technology Creates Breakthroughs in Brain Health of Military and Veterans

  7/23/2018

  New research advances the diagnosis of concussions and PTSD for those in the line of duty

• EY Announces Kevin Hrusovsky, President, Chairman and Chief Executive Officer of Quanterix and Founder of Powering Precision Health as an Entrepreneur Of The Year® 2018 Award Finalist in the New England Region

  6/13/2018

  Quanterix Corporation announced that Kevin Hrusovsky, President, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been named by EY as a finalist for the Entrepreneur Of The Year® 2018 Award in the New England program.

• Quanterix to Release First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018

  5/2/2018

  Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2018 after the close of trading on Wednesday, May 9, 2018

• Quanterix Marks Leadership in Accelerating Neurology Research with 100-Publication Milestone

  4/27/2018

  Researchers are increasingly choosing Quanterix’ ultra-sensitive technology to power advancements in neurology

• Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection

  3/20/2018

  Collaboration offers potential for PCR-free microRNA biomarker detection with high-specificity and ultra-sensitivity